Suppr超能文献

使用Summit Autonomous LADARVision准分子激光系统,对近视度数高达-11屈光度、散光度数高达-5屈光度的患者进行准分子原位角膜磨镶术。

Laser in situ keratomileusis for myopia up to -11 diopters with up to -5 diopters of astigmatism with the summit autonomous LADARVision excimer laser system.

作者信息

McDonald M B, Carr J D, Frantz J M, Kozarsky A M, Maguen E, Nesburn A B, Rabinowitz Y S, Salz J J, Stulting R D, Thompson K P, Waring G O

机构信息

Southern Vision Institute, New Orleans, Louisiana, USA.

出版信息

Ophthalmology. 2001 Feb;108(2):309-16. doi: 10.1016/s0161-6420(00)00528-5.

Abstract

OBJECTIVE

To assess the safety and effectiveness of the Summit Autonomous LADARVision active tracking narrow beam excimer laser system for laser in situ keratomileusis (LASIK) correction of myopia and astigmatism.

DESIGN

A multicenter, prospective noncomparative case series.

PARTICIPANTS

This cohort consisted of 177 eyes corrected for spherical myopia up to -11 diopters (D) and 170 eyes corrected for myopia up to -11 D spherical equivalent with astigmatism up to -5 D.

INTERVENTION

Treatments were performed at four sites in the United States using a 6-mm optic zone for spherical myopes and a 5.5-mm optic zone with a 1-mm blend for astigmats.

MAIN OUTCOME MEASURES

Visual acuity, subjective refraction, vector analysis, subject satisfaction, intraocular pressure, complications, and adverse reactions.

RESULTS

Six-month follow-up was available on 157 spherical eyes and 113 astigmatic eyes. For spherical myopes, uncorrected visual acuity (UCVA) was 20/20 or better in 60.5%, 20/25 or better in 80.3%, and 20/40 or better in 93.9%. The mean spherical equivalent was -0.29 +/- 0.45 D with 75.2% +/- 0.50 D and 94.9% +/- 1.00 D of intended. A loss of two lines of best spectacle-corrected visual acuity (BSCVA) occurred in 0.6%, and no eyes lost greater than two lines of BSCVA. For astigmatic myopes, UCVA was 20/20 or better in 52.0%, 20/25 or better in 74.5%, and 20/40 or better in 94.1%. The mean spherical equivalent was -0.23 +/- 0.49 D with 75.2% +/- 0.50 D and 95.6% +/- 1.00 D of intended. A loss of two lines of BSCVA occurred in 0.9%, and no eyes lost greater than two lines of BSCVA. Vector analysis showed that 99% of the intended cylinder was corrected on average with a mean angle of error of 4.2 degrees. Refractive stability was achieved between 1 and 3 months in 97.5% of spherical eyes and 99.4% of astigmatic eyes and confirmed between 3 and 6 months in 100% of both spherical and astigmatic eyes.

CONCLUSIONS

Eyes treated for myopia up to -11 D of spherical equivalent with or without astigmatism up to -5 D show early refractive stability, good UCVA outcomes, no significant loss of BSCVA, accurate correction of astigmatism, and slight undercorrection without a change from the photorefractive keratectomy algorithm and with a single treatment.

摘要

目的

评估Summit Autonomous LADARVision主动跟踪窄光束准分子激光系统用于准分子原位角膜磨镶术(LASIK)矫正近视和散光的安全性和有效性。

设计

一项多中心、前瞻性非对照病例系列研究。

参与者

该队列包括177只矫正球镜近视达-11屈光度(D)的眼睛以及170只矫正球镜等效近视达-11 D且散光达-5 D的眼睛。

干预

在美国的四个地点进行治疗,对于球镜近视患者使用6毫米的光学区,对于散光患者使用5.5毫米的光学区并带有1毫米的融合区。

主要观察指标

视力、主观验光、矢量分析、患者满意度、眼压、并发症及不良反应。

结果

对157只球镜眼和113只散光眼进行了6个月的随访。对于球镜近视患者,未矫正视力(UCVA)达到20/20或更好的比例为60.5%,达到20/25或更好的比例为80.3%,达到20/40或更好的比例为93.9%。平均球镜等效度数为-0.29±0.45 D,达到预期度数的75.2%±0.50 D以及94.9%±1.00 D。最佳矫正视力(BSCVA)下降两行的发生率为0.6%,且没有眼睛的BSCVA下降超过两行。对于散光近视患者,UCVA达到20/20或更好的比例为52.0%,达到20/25或更好的比例为74.5%,达到20/40或更好的比例为94.1%。平均球镜等效度数为-0.23±0.49 D,达到预期度数的75.2%±0.50 D以及95.6%±1.00 D。BSCVA下降两行的发生率为0.9%,且没有眼睛的BSCVA下降超过两行。矢量分析显示,平均矫正了99%的预期柱镜度数,平均角度误差为4.2度。97.5%的球镜眼和99.4%的散光眼在1至3个月时实现了屈光稳定,在3至6个月时,球镜眼和散光眼的屈光稳定率均为100%。

结论

矫正球镜等效近视达-11 D、伴有或不伴有散光达-5 D的眼睛,经单次治疗后显示出早期屈光稳定、良好的UCVA结果、BSCVA无显著下降、散光矫正准确且欠矫轻微,且未改变光屈光性角膜切削术算法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验